FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer

Author： Lee Jae   Orita Hajime   Gabrielson Kathleen   Alvey Sara   Hagemann Ruth   Kuhajda Francis   Gabrielson Edward   Pomper Martin  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.24, Iss.6, 2007-06, pp. : 1202-1207

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDG-PET worthwhile in head and neck cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 346, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 483-494

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Fatty Acid Synthase by Polyphenols

By  

Current Medicinal Chemistry, Vol. 13, Iss. 8, 2006-04 ,pp. : 967-977

Bentham Science Publishers

Access to resources Recommend Favorite

An integrated pharmacokinetic–pharmacodynamic model for an Aurora kinase inhibitor

By Kamei Hiroko   Jackson Robert   Zheleva Daniella   Davidson Fordyce  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 37, Iss. 4, 2010-08 ,pp. : 407-434

Springer Publishing Company

Access to resources Recommend Favorite

The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 3, 2013-03 ,pp. : 300-312

Bentham Science Publishers

Access to resources Recommend Favorite